Zhou Ping, Xiong Tingchuan, Chen Jingxin, Li Fen, Qi Tingting, Yuan Jianlin
Department of Gynecology and Obstetrics, Cancer Hospital Affiliated to Xinjiang Medical University, Wulumuqi, Xinjiang 830011, P.R. China.
Department of Gynaecology and Obstetrics, Dongfang Hospital Affiliated to Tongji University, Shanghai 200120, P.R. China.
Oncol Lett. 2019 Feb;17(2):2418-2424. doi: 10.3892/ol.2018.9840. Epub 2018 Dec 17.
Ovarian cancer is the fifth most common type of cancer in females; however, its asymptomatic progression and the lack of an efficient screening strategy leads to late diagnosis. The present study aimed to investigate the expression levels of cluster of differentiation (CD)146 and vascular endothelial growth factor A (VEGFA) in epithelial ovarian cancer, and their clinical significance. A total of 52 ovarian samples were tested, of which 22 were from patients with epithelial ovarian cancer and 30 were from non-cancer patients. The relative gene expression of CD146 and VEGFA was quantified using reverse transcription-quantitative polymerase chain reaction analysis. Western blotting was used to determine the protein expression levels. The relative gene expression levels of CD146 and VEGFA in tumor tissues were significantly increased compared with the control (4.92±0.44 vs. 1.05±0.06 and 3.08±0.17 vs. 1.06±0.07, P<0.01). The protein expression levels of CD146 and VEGFA in tumor tissue were also significantly increased compared with the control (0.70±0.02 vs. 0.41±0.07 and 0.54±0.01 vs. 0.26±0.01, P<0.01). There was a positive correlation between the expression levels of CD146 and VEGFA genes (r=0.78) and between the two proteins (r=0.69). Dot density frequency analysis indicated that CD146 and VEGFA were specifically present in tumor tissues. In conclusion, CD146 and VEGFA are co-overexpressed in ovarian cancer; their potential as tumor biomarkers or therapeutic targets for the treatment of ovarian cancer requires further investigation.
卵巢癌是女性中第五大常见癌症类型；然而，其无症状进展以及缺乏有效的筛查策略导致诊断延迟。本研究旨在调查分化簇（CD）146和血管内皮生长因子A（VEGFA）在上皮性卵巢癌中的表达水平及其临床意义。共检测了52份卵巢样本，其中22份来自上皮性卵巢癌患者，30份来自非癌症患者。使用逆转录-定量聚合酶链反应分析定量CD146和VEGFA的相对基因表达。采用蛋白质印迹法测定蛋白质表达水平。与对照组相比，肿瘤组织中CD146和VEGFA的相对基因表达水平显著升高（4.92±0.44对1.05±0.06以及3.08±0.17对1.06±0.07，P<0.01）。与对照组相比，肿瘤组织中CD146和VEGFA的蛋白质表达水平也显著升高（0.70±0.02对0.41±0.07以及0.54±0.01对0.26±0.01，P<0.01）。CD146和VEGFA基因表达水平之间呈正相关（r=0.78），两种蛋白质之间也呈正相关（r=0.69）。点密度频率分析表明CD146和VEGFA特异性存在于肿瘤组织中。总之，CD146和VEGFA在卵巢癌中共同过度表达；它们作为肿瘤生物标志物或卵巢癌治疗靶点的潜力需要进一步研究。
